Kidney Cancer (@KCA_Journal) header
Kidney Cancer (@KCA_Journal) profile picture

Kidney Cancer

@KCA_Journal

Editors-in-Chief: Primo N. Lara Jr., MD, and Peter Mulders, MD | Dedicated to expediting our understanding & improving treatments of kidney cancer

 SoMeEditor
journalkidneycancer.com
Joined June 2017
  • Tweets737
  • Following690
  • Followers1.5K
📢 Call for Papers‼️ We invite you to submit your manuscript to, One of the world's leading journals in GU Oncology, Kidney Cancer! For more information and detailed submission guidelines, visit 8ifi.short.gy/CFP_KCA @IOSPress_STM @primolara @oncoalert @urotoday #KidneyCancer
Image from Kidney Cancer (@KCA_Journal)
1
9
1
11
3,755
Out now in @JCO_ASCO and @CircAHA: Our @American_Heart & @ASCO joint scientific statement on defining cardiovascular (CV) endpoints in oncology trials👉a framework for asking CV safety questions before trials begin👉Article link in the last post 👇#CardioOncology #CardioTwitter. @OncoAlert @US_FDA
🤖 Made with AI
Image from Neeraj Agarwal, MD, FASCO (@neerajaiims)
Image from Neeraj Agarwal, MD, FASCO (@neerajaiims)
Image from Neeraj Agarwal, MD, FASCO (@neerajaiims)
8
56
12
119
31,373
Breaking news from #ESMO25 in Berlin 👉Randomized trial of Pluvicto/Lu-177 vs. docetaxel (DOC) in 199 pts with mCRPC #prostatecancer 👉progressing after ARPI therapy👉Similar PFS (primarily endpoint) but higher OS with docetaxel👇#KimChi #ESMO25 @OncoAlert @urotoday @PCF_Science
Image from Neeraj Agarwal, MD, FASCO (@neerajaiims)
Image from Neeraj Agarwal, MD, FASCO (@neerajaiims)
Image from Neeraj Agarwal, MD, FASCO (@neerajaiims)
Image from Neeraj Agarwal, MD, FASCO (@neerajaiims)
6
89
7
172
18,407
Kidney Cancer retweeted
ASCO (@ASCO) profile picture
ASCO
@ASCO30 Jun 2025
🎙 @neerajaiims of @huntsmancancer and Dr. Jeanny Aragon-Ching of @InovaSchar highlight key innovations in GU cancer research from #ASCO25 on a new episode of the #ASCODailyNews Podcast: bit.ly/4elzewZ
Image from ASCO (@ASCO)
1
21
4
37
13,982
Just in @JAMANetworkOpen👉@flatironhealth Real world Rx data from >8500 pts w/ mRCC #kidneycancer 👉After 2018, only 38% & 14% of pts received 2nd & 3rd line Rx respectively👇bit.ly/41H22dp Thanks to my mentors @umangtalking @montypal @neerajaiims Cc @OncoAlert @urotoday
Image from Zeynep Irem Ozay, MD (@ziremozay)
Image from Zeynep Irem Ozay, MD (@ziremozay)
Image from Zeynep Irem Ozay, MD (@ziremozay)
Image from Zeynep Irem Ozay, MD (@ziremozay)
6
41
5
96
28,634
Looking forward to spending the evening after a terrific day at @ASCO #GU25 w @DrRanaMcKay @TiansterZhang & @DrTHut! Come join us at 6 pm Friday evening at the @Marriott Marquis, just down the street from Moscone!
Image from Sumanta K. Pal, MD, FASCO (@montypal)
13
1
45
2,340
COSMIC-313: Addition of Cabozantinib to Ipi+nivo overcomes M2-like macrophage-mediated immune suppression @AlbigesL 👇@DrChoueiri @motzermd @urotoday @kidneycan @OncoAlert #GU25 @ASCO #kidneycancer
Image from Neeraj Agarwal, MD, FASCO (@neerajaiims)
Image from Neeraj Agarwal, MD, FASCO (@neerajaiims)
Image from Neeraj Agarwal, MD, FASCO (@neerajaiims)
Yüksel Ürün (@DrYukselUrun) profile pictureYüksel Ürün
@DrYukselUrun15 Feb 2025
COSMIC-313: Final OS Analysis @AlbigesL Cabo+Nivo+Ipi (C+N+I) maintains PFS & ORR benefits vs. Placebo+N+I in 1L IMDC intermediate/poor risk aRCC. No OS difference between arms 🧬 High M2 macrophage abundance linked to improved OS with C+N+I #GU25 @asco #kidneycancer #cancer #oncology @dryukselurun @MikeSerzanMD @drenriquegrande @crisbergerot @reginabarcar @DRBakaloudiMD @ReneeSaliby @yekeduz_emre @neerajaiims @PGrivasMDPhD @CParkMD @OncLive @apolo_andrea @tompowles1 @Uromigos @TiansterZhang @ERPlimackMD @OncBrothers
Image from Yüksel Ürün (@DrYukselUrun)
Image from Yüksel Ürün (@DrYukselUrun)
Image from Yüksel Ürün (@DrYukselUrun)
Image from Yüksel Ürün (@DrYukselUrun)
21
1
36
4,405
Good morning, @ASCO #GU25! ☀️ Ready to kick off the third and final day! Starting with the poster session on RCC, penile, and testicular cancer, followed by oral abstracts, biomarkers & adjuvant therapy for RCC, trials in progress, and a case-based session (failure on immuno)
Image from Cristiane D Bergerot, PhD, FASCO (@crisbergerot)
Image from Cristiane D Bergerot, PhD, FASCO (@crisbergerot)
Image from Cristiane D Bergerot, PhD, FASCO (@crisbergerot)
6
10
2,562
Kidney Cancer retweeted
Jun Gong, MD (@jgong15) profile picture
Jun Gong, MD@jgong1515 Feb 2025
Replying to @katy_beckermann
@katy_beckermann KEYMAKER-UO3 PhI/II #accRCC after #IO-based tx (>50% >3 prior lines) ➡️ Len/belzutifan higher ORR 47% vs Len/pembro 40% vs pembro/belzut 19% w/higher PFS for len + belzutifan (12.5 mos). OS not mature. Interesting activity for Len/belzutifan #GU25 @OncoAlert
Image from Jun Gong, MD (@jgong15)
Image from Jun Gong, MD (@jgong15)
Image from Jun Gong, MD (@jgong15)
Image from Jun Gong, MD (@jgong15)
11
13
928
⭐️ Top 10 #GU25 Influencers so far at ASCO GU. @ASCO @neerajaiims @OncoAlert @DrChoueiri @crisbergerot @montypal @tompowles1 @yekeduz_emre @PGrivasMDPhD Top 10 highest impressions totaling 50+ million impressions @OncoAlert @ASCO @urotoday @OncLive @weoncologists @NazliDizman
Image from 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 (@CParkMD)
Image from 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 (@CParkMD)
2
16
31
2,201
Final #CheckMate9ER results (5+ yr FU: N+C > S in 1L #aRCC PFS HR 0.58, OS HR 0.79, ORR 55.7% vs 27.4%. No new safety signals. N+C remains a SOC for untreated aRCC. @ASCO #GU25 @motzermd @tompowles1 @MSKCancerCenter @OncoAlert
Image from Toni Choueiri, MD (@DrChoueiri)
Image from Toni Choueiri, MD (@DrChoueiri)
23
2
43
11,062
Congrats to @DrChoueiri @motzermd for developing one of the most effective combinations cabozantinib + nivolumab for mRCC #kidneycancer 👉Checkmate 9ER phase 3 trial👉continued strong OS benefit @tompowles1 @AlbigesL @asco #GU25 @OncoAlert @urotoday @kidneycan @KidneyCancer 👇
Image from Neeraj Agarwal, MD, FASCO (@neerajaiims)
Image from Neeraj Agarwal, MD, FASCO (@neerajaiims)
Image from Neeraj Agarwal, MD, FASCO (@neerajaiims)
Toni Choueiri, MD (@DrChoueiri) profile pictureToni Choueiri, MD
@DrChoueiri15 Feb 2025
Final #CheckMate9ER results (5+ yr FU: N+C > S in 1L #aRCC PFS HR 0.58, OS HR 0.79, ORR 55.7% vs 27.4%. No new safety signals. N+C remains a SOC for untreated aRCC. @ASCO #GU25 @motzermd @tompowles1 @MSKCancerCenter @OncoAlert
Image from Toni Choueiri, MD (@DrChoueiri)
Image from Toni Choueiri, MD (@DrChoueiri)
1
22
1
51
6,695
Outstanding talk and discussion on emerging treatment landscape of mRCC #kidneycancer by @TiansterZhang 👉 emphasizes the need to personalize treatment in mRCC #kidneycancer 👉next gen trials 👇@urotoday @kidneycan @OncoAlert @KidneyCancer #GU25 @ASCO @apolo_andrea
Image from Neeraj Agarwal, MD, FASCO (@neerajaiims)
Image from Neeraj Agarwal, MD, FASCO (@neerajaiims)
Image from Neeraj Agarwal, MD, FASCO (@neerajaiims)
Image from Neeraj Agarwal, MD, FASCO (@neerajaiims)
Yüksel Ürün (@DrYukselUrun) profile pictureYüksel Ürün
@DrYukselUrun15 Feb 2025
Eye opener discussion @TiansterZhang ASCO GU 2025: Clear Cell RCC – Beyond the Dichotomy 🔬 ccRCC is not a monolith! 🧬 Molecular complexity: VHL, PBRM1, SETD2, BAP1 📊 Transcriptomic clusters & tumor microenvironment drive heterogeneity 🚀 Precision medicine is key! #GU25 @asco #kidneycancer #cancer #oncology @DrChoueiri @dryukselurun @MikeSerzanMD @drenriquegrande @crisbergerot @reginabarcar @DRBakaloudiMD @ReneeSaliby @yekeduz_emre @neerajaiims @PGrivasMDPhD @CParkMD @OncLive @apolo_andrea @OncoBellmunt @sonpavde @MattGalsky @tompowles1 @Uromigos @kalasri3 @TiansterZhang @AndreaNecchi @ERPlimackMD @OncBrothers
Image from Yüksel Ürün (@DrYukselUrun)
Image from Yüksel Ürün (@DrYukselUrun)
Image from Yüksel Ürün (@DrYukselUrun)
Image from Yüksel Ürün (@DrYukselUrun)
21
1
46
4,531
Have been so impressed w @mzugman. After joining us at @cityofhope from @hosp_einstein, he has been prolific with multiple papers, abstracts & ISTs. He wrote the paper in @OncJournal below & offers terrific insights on this updated data from #TIVO3, pointing to durable benefits with #tivozanib particularly in the #ICI pre-treated population. @brian_rini @DrTHut @CPRT65 @elena_verzoni @Uromigos @neerajaiims @DrChoueiri @KidneyCancer @kidneycan
Miguel Zugman, MD (@mzugman) profile pictureMiguel Zugman, MD@mzugman6 Feb 2025
1/7 Pleased to share updated OS results from the #TIVO-3 study (NCT02627963), previously presented at #ESMO24. Our analysis focused on outcomes in patients with #ccRCC who had received prior treatment with a checkpoint inhibitor (CPI) - representing 26% of the trial population.
Image from Miguel Zugman, MD (@mzugman)
10
1
20
3,295
Just in @MedCellPress 👉Excellent viewpoint by our trainee, Chadi @chadihc98 👉The novel Zirconium-girentuximab PET-CT is set to change the diagnostic paradigm of ccRCC #kidneycancer (akin to PSMA-PET in #prostatecancer)👇 bit.ly/48LBPgB @ggebraelmd @urotoday @OncoAlert
Image from Neeraj Agarwal, MD, FASCO (@neerajaiims)
Image from Neeraj Agarwal, MD, FASCO (@neerajaiims)
Image from Neeraj Agarwal, MD, FASCO (@neerajaiims)
Image from Neeraj Agarwal, MD, FASCO (@neerajaiims)
2
41
2
99
15,161
Join us👉"Premier symposium on Transformation in Cancer Care Delivery" in Salt Lake City, Feb 17-19👉on new models in cancer care (screening to treatment to survivorship)👉Link: bit.ly/3YhHTc6 @huntsmancancer@UUtah @NeliMUlrich @AmericanCancer @OncoAlert @OncBrothers
Image from Neeraj Agarwal, MD, FASCO (@neerajaiims)
Image from Neeraj Agarwal, MD, FASCO (@neerajaiims)
Image from Neeraj Agarwal, MD, FASCO (@neerajaiims)
Image from Neeraj Agarwal, MD, FASCO (@neerajaiims)
1
17
1
30
11,350
Just in @Annals_Oncology 👉on the heels of the recent approval of belzutifan in mRCC #kidneycancer , herein we show in a ph2 randomized trial👉more belzutifan (200 mg vs 120 mg QD) was not better👇Link: tinyurl.com/nrsxp8s4 @urotoday @OncoAlert @kidneycan @huntsmancancer
Image from Neeraj Agarwal, MD, FASCO (@neerajaiims)
Image from Neeraj Agarwal, MD, FASCO (@neerajaiims)
Image from Neeraj Agarwal, MD, FASCO (@neerajaiims)
11
51
10
135
61,022
Just in @KCA_Journal👉Interesting systematic review by #AlfredoDistante @SMuselaers on pt selection for active surveillance of small renal masses #kidneycancer👉Age, cardiovascular index & CKD were associated with⬇️OS👇 tinyurl.com/2ty3dna5 @OncoAlert @urotoday @kidneycan
Image from Kidney Cancer (@KCA_Journal)
Image from Kidney Cancer (@KCA_Journal)
Image from Kidney Cancer (@KCA_Journal)
Image from Kidney Cancer (@KCA_Journal)
6
10
1,351
Just in @KCA_Journal 👉Excellent review by @AJangMD @ShilpaOnc on papillary RCC #kidneycancer👉Despite improved outcomes with VEGF-TKIs and ICIs, more dedicated clinical trials to pRCC are urgently needed👇 tinyurl.com/4cpsha2p @urotoday @OncoAlert @kidneycan @KidneyCancer
Image from Kidney Cancer (@KCA_Journal)
Image from Kidney Cancer (@KCA_Journal)
Image from Kidney Cancer (@KCA_Journal)
Image from Kidney Cancer (@KCA_Journal)
2
15
23
2,731
Just in @KCA_Journal 👉Interesting study by #LunavandenBrink @Zondervan_AUMC comparing outcomes of radical vs. partial nephrectomy in pts w/ cT1b RCC #kidneycancer👉10-year survival rates were similar between both groups👇 tinyurl.com/bdzm9b5b @urotoday @OncoAlert @kidneycan
Image from Kidney Cancer (@KCA_Journal)
Image from Kidney Cancer (@KCA_Journal)
Image from Kidney Cancer (@KCA_Journal)
Image from Kidney Cancer (@KCA_Journal)
3
6
685
Just in @KCA_Journal 👉Excellent review by #AlbertLee @jamesbyu on the role of radiation therapy (SBRT) in the Rx of localized and oligometastatic RCC #kidneycancer👉SBRT use will likely increase in the future 👇👇 tinyurl.com/y3upcu8m @urotoday @OncoAlert @kidneycan
Image from Kidney Cancer (@KCA_Journal)
Image from Kidney Cancer (@KCA_Journal)
Image from Kidney Cancer (@KCA_Journal)
Image from Kidney Cancer (@KCA_Journal)
7
1
15
1,956
Load more